Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 4Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Tumor Malignancies 1Carcinoma, Non-Small-Cell Lung 1Advanced or Recurrent Solid Tumors 1

Interventions

pembrolizumab 126Carboplatin 108Pemetrexed 76Paclitaxel 76Cisplatin 73Nivolumab 56Docetaxel 53Erlotinib Hydrochloride 50Gemcitabine 49Radiotherapy 48Bevacizumab 32osimertinib 31Cetuximab 29atezolizumab 25Cyclophosphamide 25durvalumab 24130-nm albumin-bound paclitaxel 22Oxaliplatin 19Fluorouracil 18Taxes 17Radiosurgery 17fludarabine 16Magnetic Resonance Spectroscopy 16Gefitinib 16Ipilimumab 15Vinorelbine 14Leucovorin 14Albumin-Bound Paclitaxel 14Vorinostat 13Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Non-Small-Cell Lung × vadimezan × Clear all
NCT00674102 2020-12-09

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Novartis

Phase 1 Completed
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡